Laboratory findings in psoriatic arthritis

Reumatismo

Volumn 59, Issue SUPPL. 1, 2007, Pages 52-55

  Punzi, Leonardo ^a   Podswiadek, M ^a   Oliviero, F ^a   Lonigro, A ^a   Modesti, V ^a   Ramonda, R ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Laboratory investigations arthritis; Psoriatic arthritis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; HLA C ANTIGEN; HLA CW6; HLA DR7 ANTIGEN; HLA-CW6; IMMUNOLOGIC FACTOR; RHEUMATOID FACTOR;

ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; METABOLISM; PREDICTIVE VALUE; PSORIATIC ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYNOVIAL FLUID;

ARTHRITIS, PSORIATIC; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HLA-C ANTIGENS; HLA-DR7 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID;

EID: 69949143704     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2007.1s.52     Document Type: Article

References (36)

1. Moll JMN, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 51-78.
2. Berthelot JM. Psoriatic arthritis as a mountain. Reumatismo 2003; 55: 6-15.
3. Punzi L, Podswiadek M, Oliviero F, Sfriso P, Fiocco U, Todesco S. Pathogenetic and clinical rationale for anti-TNF blocking in psoriatic arthritis. Autoimmunity Review, in press.
4. Gladmann D, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis: clinical and laboratory analysis of 220 patients. Q J Med 1987; 62: 127-41.
5. Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. Am Acad Dermatol 2004; 52: 1-19.
6. Helliwell PS, Porter G, Taylor WJ. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis, 2007; 66: 113-7.
7. Bogliolo L, Alpini C, Caporali R, Sciré CA, Moratti R, Montecucco CM. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32: 511-5.
8. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis. A review of currently available measures. Arthritis Rheum 2004; 50: 24-35.
9. Cervini C, Leardini G, Mathieu A, Punzi L, Scarpa R. Psoriatic arthritis: epidemiological and clinical aspects in a cohort of 1.306 italian patients. Reumatismo 2005; 57: 283-90.
10. Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999; 58: 226-9.
11. Punzi L, Pianon M, Gambari PF. Normal values of laboratory tests in elderly onset psoriatic arthritis. Ann Rheum Dis 2000; 59: 239-40.
12. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-8.
13. Punzi L, Bertazzolo N, Pianon M, Michelotto M, Cesaro G, Gambari PF. The volume of synovial fluid effusion in psoriatic arthritis. Clin Exp Rheumatol. 1995; 13: 535-6.
14. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993; 36: 893-900.
15. Fiocco U, Cozzi L, Chieco-Bianchi F, Rigon C, Vezzu M, Favero E, et al. Vascular changes in psoriatic knee joint synovitis. J Rheumatol 2001; 28: 2480-6.
16. Fearon U, Reece R, Smith J, Emery P, Veale DJ. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci 1999; 878: 619-21.
17. Kane DJ, Saxne T, Doran JP, Bresnihan B, FitzGerald O. A comparison of the ESR, CRP, serum amyloid A and cartilage oligomeric matrix protein in assessing inflammation and predicting radiological outcome in eraly psoriatic arthritis. Arthritis rheum 2003; 48 (suppl 9): s178 (Abstract).
18. Pipitone N, Kingsley GH, Manzo A, Scott DL, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford). 2003; 42: 1138-48.
19. Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999; 26: 2409-13.
20. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indiators of death. Arthritis Rheum 1998; 41: 1103-10.
21. Punzi L, Bertazzolo N, Pianon M, Rizzi E, Rossini P, Gambari PF. Value of synovial fluid interleukin-1 beta determination in predicting the outcome of psoriatic arthritis. Ann Rheum Dis 1996; 55: 642-4
22. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.
23. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109: 562-5.
24. Balding J, Kane D, Lingstone W, Mynett-Johnson L, Bresnihan B, Smith O, et al. Cytokine Gene Polymorphisms: Associations with Psoriatic Arthritis Susceptibility and Severity. Arthritis Rheum 2003;48:1408-13
25. Henseler T. The genetic of psoriasis. J Am Acad Dermatol 1997; 37: S1-11.
26. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis. Hum Immunol 1999; 60: 259-61.
27. Hohler T, Marker-Hermann E. Psoriatic arthritis: clinical aspects, genetics, and the role of T cells. Curr Opin Rheumatol 2001; 13: 273-9.
28. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64 (suppl II): ii37-ii39.
29. Gudjonsson JE, Karason A, Antonsdottir AA, Runarsdottir EH, Gulcher JR, Stefansson K, et al. HLA-CW6-positive and HLA-CW6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-5.
30. Mallon E, Bunce M, Savoie H, Rowe A, Newson R, Gotch F, et al. HLA-C and guttate psoriasis. Br J Dermatol 2000; 143: 1177-82.
31. Gladman DD, Farewell VT, Rahman P, Schentag CT, Pellett F, Ng CM, Wade JA. HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. Hum Immunol. 2001; 62: 1239-44.
32. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90
33. Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther 2006; 6: 99-107.
34. Salvarani C, Olivieri I, Cantini F, Marchesoni A, Punzi L, Scarpa R, et al. Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis of Italian Rheumatology Society. Reumatismo 2004; 56: 136-8.
35. Pham T, Guillemin F, Claudepierre P, Luc M, Miceli-Richard C, Fautrel B, et al. TNF antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society of Rheumatology. Joint Bone Spine 2006; 73: 547-53.
36. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three month, randomised, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.